Pembrolizumab + Nivolumab

How it works

Blocks PD-1, a protein on immune cells that normally helps regulate immune responses, allowing the immune system to attack cancer cells more effectively.

Cancer types

Efficacy

Studies show that around 50% of patients achieved an objective response, with a median overall survival of approximately 10 months.

Side effects